{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:34:16Z","timestamp":1784043256878,"version":"3.55.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"DOI":"10.7759\/cureus.78462","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:23:26Z","timestamp":1738650206000},"source":"Crossref","is-referenced-by-count":5,"title":["Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies"],"prefix":"10.7759","author":[{"given":"Akshita","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Shahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurima","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Safa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vindlacheruvu","family":"Srividya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchira","family":"Clementina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goutham  R","family":"Anugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Younas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen MJ","year":"2015","unstructured":"Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015, 169:1053-60. 10.1001\/jamapediatrics.2015.1982","journal-title":"JAMA Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i20.3204","article-title":"Pediatric inflammatory bowel disease","volume":"12","author":"Diefenbach KA","year":"2006","unstructured":"Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006, 12:3204-12. 10.3748\/wjg.v12.i20.3204","journal-title":"World J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/365712","article-title":"Impact of inflammatory bowel disease upon growth in children and adolescents","volume":"2011","author":"Moeeni V","year":"2011","unstructured":"Moeeni V, Day AS. Impact of inflammatory bowel disease upon growth in children and adolescents. ISRN Pediatr. 2011, 2011:365712. 10.5402\/2011\/365712","journal-title":"ISRN Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3182841263","article-title":"Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition","volume":"56","author":"Mackner LM","year":"2013","unstructured":"Mackner LM, Greenley RN, Szigethy E, Herzer M, Deer K, Hommel KA. Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2013, 56:449-58. 10.1097\/MPG.0b013e3182841263","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2016.59.6.247","article-title":"Nutritional concerns in pediatric inflammatory bowel disease","volume":"59","author":"Kim YJ","year":"2016","unstructured":"Kim YJ. Nutritional concerns in pediatric inflammatory bowel disease. Korean J Pediatr. 2016, 59:247-51. 10.3345\/kjp.2016.59.6.247","journal-title":"Korean J Pediatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz182","article-title":"Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016","volume":"26","author":"Ye Y","year":"2020","unstructured":"Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007-2016. Inflamm Bowel Dis. 2020, 26:619-25. 10.1093\/ibd\/izz182","journal-title":"Inflamm Bowel Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i25.2741","article-title":"Current global trends in the incidence of pediatric-onset inflammatory bowel disease","volume":"24","author":"S\u00fdkora J","year":"2018","unstructured":"S\u00fdkora J, Pomaha\u010dov\u00e1 R, Kreslov\u00e1 M, Cval\u00ednov\u00e1 D, \u0160tych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018, 24:2741-63. 10.3748\/wjg.v24.i25.2741","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig ME","year":"2022","unstructured":"Kuenzig ME, Fung SG, Marderfeld L, et al.. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022, 162:1147-1159.e4. 10.1053\/j.gastro.2021.12.282","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.paed.2018.08.007","article-title":"Paediatric inflammatory bowel disease- brief update on current practice","volume":"28","author":"Ashton JJ","year":"2018","unstructured":"Ashton JJ, Batra A, Beattie RM. Paediatric inflammatory bowel disease- brief update on current practice. Paediatr Child Health. 2018, 28:507-14. 10.1016\/j.paed.2018.08.007","journal-title":"Paediatr Child Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000483","article-title":"Pediatric IBD-unclassified is less common than previously reported; results of an 8-year audit of the EUROKIDS registry","volume":"21","author":"Winter DA","year":"2015","unstructured":"Winter DA, Karolewska-Bochenek K, Lazowska-Przeorek I, et al..  Pediatric IBD-unclassified is less common than previously reported; results of an 8-year audit of the EUROKIDS registry. Inflamm Bowel Dis. 2015, 21:2145-53. 10.1097\/MIB.0000000000000483","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21099","article-title":"Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients","volume":"16","author":"Gupta N","year":"2010","unstructured":"Gupta N, Bostrom AG, Kirschner BS, et al.. Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients. Inflamm Bowel Dis. 2010, 16:638-44. 10.1002\/ibd.21099","journal-title":"Inflamm Bowel Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10621","article-title":"Biologics targeting in the treatment of inflammatory bowel disease: a conundrum","volume":"12","author":"Rehman M","year":"2020","unstructured":"Rehman M, Cancarevic I, Iskander B, Lalani S, Malik BH. Biologics targeting in the treatment of inflammatory bowel disease: a conundrum\r\n. Cureus. 2020, 12:e10621. 10.7759\/cureus.10621","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i18.2784","article-title":"Infliximab vs adalimumab: points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease","volume":"29","author":"Kim ES","year":"2023","unstructured":"Kim ES, Kang B. Infliximab vs adalimumab: points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease. World J Gastroenterol. 2023, 29:2784-97. 10.3748\/wjg.v29.i18.2784","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102529","article-title":"A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease","volume":"20","author":"Aardoom MA","year":"2019","unstructured":"Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease\r\n. Int J Mol Sci. 2019, 20:10.3390\/ijms20102529","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48338","article-title":"Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review","volume":"15","author":"Ashraf H","year":"2023","unstructured":"Ashraf H, Bodapati A, Hanif A, Okafor DK, Katyal G, Kaur G, Khan S.  Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review. Cureus. 2023, 15:e48338. 10.7759\/cureus.48338","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144119","article-title":"Fecal microbiota transplantation as new therapeutic avenue for human diseases","volume":"11","author":"Biazzo M","year":"2022","unstructured":"Biazzo M, Deidda G. Fecal microbiota transplantation as new therapeutic avenue for human diseases. J Clin Med. 2022, 11:4119. 10.3390\/jcm11144119","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/genes13122388","article-title":"Genetic and epigenetic etiology of inflammatory bowel disease: an update","volume":"13","author":"Jarmakiewicz-Czaja S","year":"2022","unstructured":"Jarmakiewicz-Czaja S, Zieli\u0144ska M, Sokal A, Filip R. Genetic and epigenetic etiology of inflammatory bowel disease: an update. Genes (Basel). 2022, 13:10.3390\/genes13122388","journal-title":"Genes (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i22.2715","article-title":"Familial aggregation in inflammatory bowel disease: is it genes or environment?","volume":"17","author":"Nunes T","year":"2011","unstructured":"Nunes T, Fiorino G, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: is it genes or environment?. World J Gastroenterol. 2011, 17:2715-22. 10.3748\/wjg.v17.i22.2715","journal-title":"World J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2017.0208","article-title":"Familial and ethnic risk in inflammatory bowel disease","volume":"31","author":"Santos MP","year":"2018","unstructured":"Santos MP, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol. 2018, 31:14-23. 10.20524\/aog.2017.0208","journal-title":"Ann Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i27.6296","article-title":"Environmental risk factors for inflammatory bowel diseases: evidence based literature review","volume":"22","author":"Abegunde AT","year":"2016","unstructured":"Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. 2016, 22:6296-317. 10.3748\/wjg.v22.i27.6296","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100884","article-title":"Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses","volume":"36","author":"Agrawal M","year":"2021","unstructured":"Agrawal M, Sabino J, Frias-Gomes C, et al.. Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses. EClinicalMedicine. 2021, 36:100884. 10.1016\/j.eclinm.2021.100884","journal-title":"EClinicalMedicine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04640-9","article-title":"Changing epidemiology of inflammatory bowel disease in children and adolescents","volume":"39","author":"Long D","year":"2024","unstructured":"Long D, Wang C, Huang Y, Mao C, Xu Y, Zhu Y. Changing epidemiology of inflammatory bowel disease in children and adolescents. Int J Colorectal Dis. 2024, 39:73. 10.1007\/s00384-024-04640-9","journal-title":"Int J Colorectal Dis"},{"key":"ref23","unstructured":"Centers for Disease Control and Prevention. IBD facts and stats. Inflammatory bowel disease (IBD). (2024). Accessed. November 10, 2024: https:\/\/www.cdc.gov\/inflammatory-bowel-disease\/php\/facts-stats\/index.html."},{"key":"ref24","article-title":"Puberty, developmental processes, and health interventions","author":"Viner RM","year":"2017","unstructured":"Viner RM, Allen NB, Patton GC. Puberty, developmental processes, and health interventions. Child and Adolescent Health and Development.. Bundy DA, de Silva N, Horton S, Jamison DT, Patton GC (ed): he International Bank for Reconstruction and Development\/The World Bank,  Washington (DC); 2017."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2083","article-title":"Diagnosis and management of inflammatory bowel disease in children","volume":"357","author":"Oliveira SB","year":"2017","unstructured":"Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017, 357:j2083. 10.1136\/bmj.j2083","journal-title":"BMJ"},{"key":"ref26","article-title":"Inflammatory bowel disease","author":"McDowell C","year":"2025","unstructured":"McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler G","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021, 161:1118-32. 10.1053\/j.gastro.2021.07.042","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06759-5","article-title":"Growth delay in inflammatory bowel diseases: significance, causes, and management","volume":"66","author":"Wong K","year":"2021","unstructured":"Wong K, Isaac DM, Wine E. Growth delay in inflammatory bowel diseases: significance, causes, and management. Dig Dis Sci. 2021, 66:954-64. 10.1007\/s10620-020-06759-5","journal-title":"Dig Dis Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz259","article-title":"Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies","volume":"26","author":"Ouahed J","year":"2020","unstructured":"Ouahed J, Spencer E, Kotlarz D, et al.. Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflamm Bowel Dis. 2020, 26:820-42. 10.1093\/ibd\/izz259","journal-title":"Inflamm Bowel Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rgmxen.2016.07.003","article-title":"Diagnosis and treatment of inflammatory bowel disease: First Latin American consensus of the Pan American Crohn\u2019s and Colitis Organisation","volume":"82","author":"Yamamoto-Furusho JK","year":"2017","unstructured":"Yamamoto-Furusho JK, Bosques-Padilla F, de-Paula J, et al.. Diagnosis and treatment of inflammatory bowel disease: First Latin American consensus of the Pan American Crohn\u2019s and Colitis Organisation. Rev Gastroenterol Mex. 2017, 82:46-84. 10.1016\/j.rgmxen.2016.07.003","journal-title":"Rev Gastroenterol Mex"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka K","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018, 53:305-53. 10.1007\/s00535-018-1439-1","journal-title":"J Gastroenterol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14131384","article-title":"Diagnostic procedures for inflammatory bowel disease: laboratory, endoscopy, pathology, imaging, and beyond","volume":"14","author":"Hong SM","year":"2024","unstructured":"Hong SM, Baek DH. Diagnostic procedures for inflammatory bowel disease: laboratory, endoscopy, pathology, imaging, and beyond. Diagnostics (Basel). 2024, 14:10.3390\/diagnostics14131384","journal-title":"Diagnostics (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231151293","article-title":"Use of imaging modalities for decision-making in inflammatory bowel disease","volume":"16","author":"Nancey S","year":"2023","unstructured":"Nancey S, Fumery M, Faure M, Boschetti G, Gay C, Milot L, Roblin X. Use of imaging modalities for decision-making in inflammatory bowel disease. Therap Adv Gastroenterol. 2023, 16:17562848231151293. 10.1177\/17562848231151293","journal-title":"Therap Adv Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S14555","article-title":"Appropriate use of endoscopy in the diagnosis and treatment of gastrointestinal diseases: up-to-date indications for primary care providers","volume":"3","author":"Nguyen VX","year":"2010","unstructured":"Nguyen VX, Le Nguyen VT, Nguyen CC. Appropriate use of endoscopy in the diagnosis and treatment of gastrointestinal diseases: up-to-date indications for primary care providers. Int J Gen Med. 2010, 3:345-57. 10.2147\/IJGM.S14555","journal-title":"Int J Gen Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i35.4014","article-title":"Endoscopy in inflammatory bowel disease: role in diagnosis, management, and treatment","volume":"24","author":"Spiceland CM","year":"2018","unstructured":"Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: role in diagnosis, management, and treatment. World J Gastroenterol. 2018, 24:4014-20. 10.3748\/wjg.v24.i35.4014","journal-title":"World J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002157","article-title":"Granulomas as the most useful histopathological feature in distinguishing between Crohn\u2019s disease and intestinal tuberculosis in endoscopic biopsy specimens","volume":"94","author":"Ye Z","year":"2015","unstructured":"Ye Z, Lin Y, Cao Q, He Y, Xue L.  Granulomas as the most useful histopathological feature in distinguishing between Crohn\u2019s disease and intestinal tuberculosis in endoscopic biopsy specimens. Medicine (Baltimore). 2015, 94:e2157. 10.1097\/MD.0000000000002157","journal-title":"Medicine (Baltimore)"},{"key":"ref37","unstructured":"Pediatric celiac disease (sprue). Practice essentials, background, pathophysiology. (2023). Accessed: September 17, 2024: https:\/\/emedicine.medscape.com\/article\/932104-overview."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002544","article-title":"Differentiation of colonic inflammatory bowel disease: Re-examination of paediatric inflammatory bowel disease classes algorithm with resected colon as the criterion standard","volume":"70","author":"Dhaliwal J","year":"2020","unstructured":"Dhaliwal J, Siddiqui I, Muir J, Rinawi F, Church PC, Walters TD, Griffiths AM. Differentiation of colonic inflammatory bowel disease: Re-examination of paediatric inflammatory bowel disease classes algorithm with resected colon as the criterion standard. J Pediatr Gastroenterol Nutr. 2020, 70:218-24. 10.1097\/MPG.0000000000002544","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/nu16030351","article-title":"Adverse food reactions in inflammatory bowel disease: State of the art and future perspectives","volume":"16","author":"Capobianco I","year":"2024","unstructured":"Capobianco I, Di Vincenzo F, Puca P, Becherucci G, Mentella MC, Petito V, Scaldaferri F. Adverse food reactions in inflammatory bowel disease: State of the art and future perspectives\r\n. Nutrients. 2024, 16:10.3390\/nu16030351","journal-title":"Nutrients"},{"key":"ref40","article-title":"Overlap between irritable bowel syndrome and inflammatory bowel disease","volume":"16","author":"Ford AC","year":"2020","unstructured":"Ford AC. Overlap between irritable bowel syndrome and inflammatory bowel disease\r\n. Gastroenterol Hepatol (N Y). 2020, 16:211-3.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13203183","article-title":"The earlier you find, the better you treat: red flags for early diagnosis of inflammatory bowel disease","volume":"13","author":"Cantoro L","year":"2023","unstructured":"Cantoro L, Monterubbianesi R, Falasco G, et al.. The earlier you find, the better you treat: red flags for early diagnosis of inflammatory bowel disease. Diagnostics (Basel). 2023, 13:10.3390\/diagnostics13203183","journal-title":"Diagnostics (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac216","article-title":"Creation of an inflammatory bowel disease referral pathway for identifying patients who would benefit from inflammatory bowel disease specialist consultation","volume":"29","author":"Scott FI","year":"2023","unstructured":"Scott FI, Ehrlich O, Wood D, et al.. Creation of an inflammatory bowel disease referral pathway for identifying patients who would benefit from inflammatory bowel disease specialist consultation. Inflamm Bowel Dis. 2023, 29:1177-90. 10.1093\/ibd\/izac216","journal-title":"Inflamm Bowel Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.anpede.2019.11.004","article-title":"Time to diagnosis in paediatric inflammatory bowel disease: Key points for an early diagnosis","volume":"92","author":"Mart\u00edn-de-Carpi J","year":"2020","unstructured":"Mart\u00edn-de-Carpi J, Trevi\u00f1o SJ, Muncunill GP, Mart\u00edn-Masot R, Navas-L\u00f3pez VM. Time to diagnosis in paediatric inflammatory bowel disease: Key points for an early diagnosis. An Pediatr. 2020, 92:242-1. 10.1016\/j.anpede.2019.11.004","journal-title":"An Pediatr"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i40.11246","article-title":"Disease monitoring in inflammatory bowel disease","volume":"21","author":"Chang S","year":"2015","unstructured":"Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015, 21:11246-59. 10.3748\/wjg.v21.i40.11246","journal-title":"World J Gastroenterol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13182931","article-title":"Biomarkers in IBD: what to utilize for the diagnosis?","volume":"13","author":"D'Inc\u00e0 R","year":"2023","unstructured":"D'Inc\u00e0 R, Sturniolo G. Biomarkers in IBD: what to utilize for the diagnosis?. Diagnostics (Basel). 2023, 13:10.3390\/diagnostics13182931","journal-title":"Diagnostics (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0b013e318290568a","article-title":"Parenting stress in pediatric IBD: relations with child psychopathology, family functioning, and disease severity","volume":"34","author":"Gray WN","year":"2013","unstructured":"Gray WN, Graef DM, Schuman SS, Janicke DM, Hommel KA. Parenting stress in pediatric IBD: relations with child psychopathology, family functioning, and disease severity. J Dev Behav Pediatr. 2013, 34:237-44. 10.1097\/DBP.0b013e318290568a","journal-title":"J Dev Behav Pediatr"},{"key":"ref47","article-title":"Positioning biologic therapies in the management of pediatric inflammatory bowel disease","volume":"16","author":"Breton J","year":"2020","unstructured":"Breton J, Kastl A, Conrad MA, Baldassano RN. Positioning biologic therapies in the management of pediatric inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2020, 16:400-14.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai Z","year":"2021","unstructured":"Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021, 8:765474. 10.3389\/fmed.2021.765474","journal-title":"Front Med (Lausanne)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820941179","article-title":"Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland","volume":"13","author":"Petryszyn P","year":"2020","unstructured":"Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol. 2020, 13:1756284820941179. 10.1177\/1756284820941179","journal-title":"Therap Adv Gastroenterol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease","volume":"39","author":"Stidham RW","year":"2014","unstructured":"Stidham RW, Lee TC, Higgins PD, et al.. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2014, 39:1349-62. 10.1111\/apt.12749","journal-title":"Aliment Pharmacol Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/PHMT.S64943","article-title":"Profile of infliximab in the treatment of pediatric Crohn's disease","volume":"6","author":"Kierkus J","year":"2015","unstructured":"Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther. 2015, 6:79-85. 10.2147\/PHMT.S64943","journal-title":"Pediatric Health Med Ther"},{"key":"ref52","article-title":"Effectiveness of infliximab after adalimumab failure in Crohn's disease","volume":"18","author":"Chaparro M","year":"2012","unstructured":"Chaparro M, Andreu M, Barreiro-de Acosta M, et al.. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol. 2012, 18:5219-24.","journal-title":"World J Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn's disease","volume":"6","author":"Cherry LN","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis. 2015, 6:224-33. 10.1177\/2040622315586970","journal-title":"Ther Adv Chronic Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-023-00586-7","article-title":"Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review","volume":"25","author":"Fang S","year":"2023","unstructured":"Fang S, Zhang S, Zhang C, Wang L. Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: a systematic review. Paediatr Drugs. 2023, 25:499-513. 10.1007\/s40272-023-00586-7","journal-title":"Paediatr Drugs"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-14744-9_32","article-title":"Anti-TNF therapies other than infliximab for the treatment of pediatric inflammatory bowel disease","author":"Gold S","year":"2023","unstructured":"Gold S, Cohen L. Anti-TNF therapies other than infliximab for the treatment of pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2023, 423-43. 10.1007\/978-3-031-14744-9_32","journal-title":"Inflamm Bowel Dis"},{"key":"ref56","article-title":"Infliximab","author":"Fatima R","year":"2025","unstructured":"Fatima R, Bittar K, Aziz M. Infliximab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2016.0099","article-title":"Management of complex perianal Crohn's disease","volume":"30","author":"Aguilera-Castro L","year":"2017","unstructured":"Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn's disease. Ann Gastroenterol. 2017, 30:33-44. 10.20524\/aog.2016.0099","journal-title":"Ann Gastroenterol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20212","article-title":"Anti-Saccharomyces cerevisiae antibody in pediatric Crohn\u2019s disease patients without mucosal healing is a useful marker of mucosal damage","volume":"15","author":"Kim MJ","year":"2021","unstructured":"Kim MJ, Kim E, Kang B, Lee Y, Kang ES, Choe YH. Anti-Saccharomyces cerevisiae antibody in pediatric Crohn\u2019s disease patients without mucosal healing is a useful marker of mucosal damage. Gut Liver. 2021, 15:763-70. 10.5009\/gnl20212","journal-title":"Gut Liver"},{"key":"ref59","unstructured":"ZYMFENTRA. FDA-Approved Subcutaneous Infliximab. (2024). Accessed: November 30, 2024: https:\/\/www.zymfentra.com\/clinical\/."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/581631","article-title":"Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update","volume":"2013","author":"Guo Y","year":"2013","unstructured":"Guo Y, Lu N, Bai A. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int. 2013, 2013:581631. 10.1155\/2013\/581631","journal-title":"Biomed Res Int"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318174e886","article-title":"Safety and efficacy of adalimumab in pediatric patients with Crohn disease","volume":"47","author":"Wyneski MJ","year":"2008","unstructured":"Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2008, 47:19-25. 10.1097\/MPG.0b013e318174e886","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000713","article-title":"Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease","volume":"60","author":"Fumery M","year":"2015","unstructured":"Fumery M, Jacob A, Sarter H, et al.. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015, 60:744-8. 10.1097\/MPG.0000000000000713","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013747.pub2","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn's\u00a0disease","volume":"6","author":"Okabayashi S","year":"2022","unstructured":"Okabayashi S, Yamazaki H, Yamamoto R, et al.. Certolizumab pegol for maintenance of medically induced remission in Crohn's\u00a0disease. Cochrane Database Syst Rev. 2022, 6:CD013747. 10.1002\/14651858.CD013747.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13288","article-title":"Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice","volume":"42","author":"Moon W","year":"2015","unstructured":"Moon W, Pestana L, Becker B, et al.. Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice. Aliment Pharmacol Ther. 2015, 42:428-40. 10.1111\/apt.13288","journal-title":"Aliment Pharmacol Ther"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele FM","year":"2014","unstructured":"Ruemmele FM, Veres G, Kolho KL, et al.. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014, 8:1179-207. 10.1016\/j.crohns.2014.04.005","journal-title":"J Crohns Colitis"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001850","article-title":"The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Day AS","year":"2018","unstructured":"Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The role of combination therapy in pediatric inflammatory bowel disease: a clinical report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018, 66:361-8. 10.1097\/MPG.0000000000001850","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i37.6231","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: the dawn of reactive monitoring","volume":"27","author":"Albader F","year":"2021","unstructured":"Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: the dawn of reactive monitoring. World J Gastroenterol. 2021, 27:6231-47. 10.3748\/wjg.v27.i37.6231","journal-title":"World J Gastroenterol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3390\/futurepharmacol4010017","article-title":"Biologics, small molecules, and more in inflammatory bowel disease: the present and the future","volume":"4","author":"Manrai M","year":"2024","unstructured":"Manrai M, Jha AA, Dawra S, Pachisia AV. Biologics, small molecules, and more in inflammatory bowel disease: the present and the future. Future Pharmacol. 2024, 4:279-316. 10.3390\/futurepharmacol4010017","journal-title":"Future Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.612830","article-title":"Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases","volume":"9","author":"Luzentales-Simpson M","year":"2021","unstructured":"Luzentales-Simpson M, Pang YC, Zhang A, Sousa JA, Sly LM. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 2021, 9:612830. 10.3389\/fcell.2021.612830","journal-title":"Front Cell Dev Biol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0142","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach A","year":"2023","unstructured":"Stallmach A, Atreya R, Grunert PC, Stallhofer J, de Laffolie J, Schmidt C. Treatment strategies in inflammatory bowel diseases. Dtsch Arztebl Int. 2023, 120:768-78. 10.3238\/arztebl.m2023.0142","journal-title":"Dtsch Arztebl Int"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03229-x","article-title":"Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review","volume":"22","author":"Fang S","year":"2022","unstructured":"Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr. 2022, 22:175. 10.1186\/s12887-022-03229-x","journal-title":"BMC Pediatr"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac135","article-title":"Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents","volume":"17","author":"Croft NM","year":"2023","unstructured":"Croft NM, de Ridder L, Griffiths AM, et al.. Paediatric inflammatory bowel disease: a multi-stakeholder perspective to improve development of drugs for children and adolescents. J Crohns Colitis. 2023, 17:249-58. 10.1093\/ecco-jcc\/jjac135","journal-title":"J Crohns Colitis"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051519","article-title":"Ustekinumab in the treatment of inflammatory bowel diseases: evolving paradigms","volume":"13","author":"Mocci G","year":"2024","unstructured":"Mocci G, Tursi A, Onidi FM, Usai-Satta P, Pes GM, Dore MP. Ustekinumab in the treatment of inflammatory bowel diseases: evolving paradigms. J Clin Med. 2024, 13:1519. 10.3390\/jcm13051519","journal-title":"J Clin Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"67","author":"Honap S","year":"2022","unstructured":"Honap S, Meade S, Ibraheim H, Irving PM, Jones MP, Samaan MA. Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2022, 67:1018-35. 10.1007\/s10620-021-06932-4","journal-title":"Dig Dis Sci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003758","article-title":"Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the Pediatric GETAID","volume":"76","author":"Koudsi M","year":"2023","unstructured":"Koudsi M, Martinez-Vinson C, Pigneur B, et al.. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the Pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023, 76:763-70. 10.1097\/MPG.0000000000003758","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i28.4055","article-title":"Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn's disease","volume":"26","author":"Cordes F","year":"2020","unstructured":"Cordes F, Foell D, Ding JN, Varga G, Bettenworth D. Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn's disease. World J Gastroenterol. 2020, 26:4055-75. 10.3748\/wjg.v26.i28.4055","journal-title":"World J Gastroenterol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003190","article-title":"Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease","volume":"73","author":"Moore H","year":"2021","unstructured":"Moore H, Dubes L, Fusillo S, Baldassano R, Stein R. Tofacitinib therapy in children and young adults with pediatric-onset medically refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2021, 73:e57-62. 10.1097\/MPG.0000000000003190","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010224","article-title":"The role of IL-23 inhibitors in Crohn\u2019s disease","volume":"13","author":"Fanizza J","year":"2023","unstructured":"Fanizza J, D'Amico F, Lusetti F, et al.. The role of IL-23 inhibitors in Crohn\u2019s disease. J Clin Med. 2023, 13:10.3390\/jcm13010224","journal-title":"J Clin Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt A","year":"2023","unstructured":"Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG.  Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023, 40:3410-33. 10.1007\/s12325-023-02568-0","journal-title":"Adv Ther"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub4","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"2016","author":"Wang Y","year":"2016","unstructured":"Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016, 2016:CD000544. 10.1002\/14651858.CD000544.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2022-005750","article-title":"Inflammatory bowel disease: an update","volume":"44","author":"Picoraro JA","year":"2023","unstructured":"Picoraro JA, Moore H, LeLeiko NS. Inflammatory bowel disease: an update\r\n. Pediatr Rev. 2023, 44:139-52. 10.1542\/pir.2022-005750","journal-title":"Pediatr Rev"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3182662233","article-title":"Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines","volume":"55","author":"Turner D","year":"2012","unstructured":"Turner D, Levine A, Escher JC, et al.. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012, 55:340-61. 10.1097\/MPG.0b013e3182662233","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref83","article-title":"Corticosteroid adverse effects","author":"Yasir M","year":"2025","unstructured":"Yasir M, Sonthalia S, Goyal A. Corticosteroid adverse effects. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.022","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease","volume":"157","author":"Mack DR","year":"2019","unstructured":"Mack DR, Benchimol EI, Critch J, et al.. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology. 2019, 157:320-48. 10.1053\/j.gastro.2019.03.022","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000225330.38119.c7","article-title":"Use of antibiotics in the treatment of inflammatory bowel disease","volume":"12","author":"Perencevich M","year":"2006","unstructured":"Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006, 12:651-64. 10.1097\/01.MIB.0000225330.38119.c7","journal-title":"Inflamm Bowel Dis"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012730.pub2","article-title":"Antibiotics for induction and maintenance of remission in Crohn's disease","volume":"2","author":"Townsend CM","year":"2019","unstructured":"Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R. Antibiotics for induction and maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2019, 2:CD012730. 10.1002\/14651858.CD012730.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz006","article-title":"Efficacy of combination antibiotic therapy for refractory pediatric inflammatory bowel disease","volume":"25","author":"Breton J","year":"2019","unstructured":"Breton J, Kastl A, Hoffmann N, et al.. Efficacy of combination antibiotic therapy for refractory pediatric inflammatory bowel disease\r\n. Inflamm Bowel Dis. 2019, 25:1586-93. 10.1093\/ibd\/izz006","journal-title":"Inflamm Bowel Dis"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315199","article-title":"Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial","volume":"68","author":"Levine A","year":"2019","unstructured":"Levine A, Kori M, Kierkus J, et al.. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut. 2019, 68:239-47. 10.1136\/gutjnl-2017-315199","journal-title":"Gut"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1940956","article-title":"Antibiotics in pediatric inflammatory bowel diseases: a systematic review","volume":"15","author":"Verburgt CM","year":"2021","unstructured":"Verburgt CM, Heutink WP, Kuilboer LI, et al.. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol. 2021, 15:891-908. 10.1080\/17474124.2021.1940956","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01047","article-title":"Emerging health concepts in the probiotics field: streamlining the definitions","volume":"10","author":"Mart\u00edn R","year":"2019","unstructured":"Mart\u00edn R, Langella P. Emerging health concepts in the probiotics field: streamlining the definitions. Front Microbiol. 2019, 10:1047. 10.3389\/fmicb.2019.01047","journal-title":"Front Microbiol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212506","article-title":"Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood","volume":"22","author":"Eindor-Abarbanel A","year":"2021","unstructured":"Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood. Int J Mol Sci. 2021, 22:10.3390\/ijms222212506","journal-title":"Int J Mol Sci"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S400447","article-title":"Stem cell therapy in inflammatory bowel disease: a review of achievements and challenges","volume":"16","author":"Tian CM","year":"2023","unstructured":"Tian CM, Zhang Y, Yang MF, et al.. Stem cell therapy in inflammatory bowel disease: a review of achievements and challenges. J Inflamm Res. 2023, 16:2089-119. 10.2147\/JIR.S400447","journal-title":"J Inflamm Res"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.010","article-title":"Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial","volume":"4","author":"Borrelli O","year":"2006","unstructured":"Borrelli O, Cordischi L, Cirulli M, et al.. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006, 4:744-53. 10.1016\/j.cgh.2006.03.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318235b397","article-title":"Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease","volume":"54","author":"Critch J","year":"2012","unstructured":"Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012, 54:298-305. 10.1097\/MPG.0b013e318235b397","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.09.008","article-title":"Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn\u2019s disease","volume":"18","author":"Lewis JD","year":"2015","unstructured":"Lewis JD, Chen EZ, Baldassano RN, et al..  Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn\u2019s disease. Cell Host Microbe. 2015, 18:489-500. 10.1016\/j.chom.2015.09.008","journal-title":"Cell Host Microbe"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.04.021","article-title":"Crohn\u2019s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial","volume":"157","author":"Levine A","year":"2019","unstructured":"Levine A, Wine E, Assa A, et al.. Crohn\u2019s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019, 157:440-450.e8. 10.1053\/j.gastro.2019.04.021","journal-title":"Gastroenterology"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001800","article-title":"Personalized research on diet in ulcerative colitis and Crohn\u2019s disease: a series of N-of-1 diet trials","volume":"117","author":"Kaplan HC","year":"2022","unstructured":"Kaplan HC, Opipari-Arrigan L, Yang J, et al.. Personalized research on diet in ulcerative colitis and Crohn\u2019s disease: a series of N-of-1 diet trials. Am J Gastroenterol. 2022, 117:902-17. 10.14309\/ajg.0000000000001800","journal-title":"Am J Gastroenterol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003425","article-title":"The impact of compliance during exclusive enteral nutrition on fecal calprotectin in children with Crohn\u2019s disease","volume":"74","author":"Mckirdy S","year":"2022","unstructured":"Mckirdy S, Russell RK, Svolos V, Gkikas K, Logan M, Hansen R, Gerasimidis K. The impact of compliance during exclusive enteral nutrition on fecal calprotectin in children with Crohn\u2019s disease\r\n. J Pediatr Gastroenterol Nutr. 2022, 74:801-4. 10.1097\/MPG.0000000000003425","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15598","article-title":"Fecal microbiota transplantation therapy in Crohn's disease: systematic review","volume":"36","author":"Fehily SR","year":"2021","unstructured":"Fehily SR, Basnayake C, Wright EK, Kamm MA. Fecal microbiota transplantation therapy in Crohn's disease: systematic review. J Gastroenterol Hepatol. 2021, 36:2672-86. 10.1111\/jgh.15598","journal-title":"J Gastroenterol Hepatol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab202","article-title":"Efficacy and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in children with inflammatory bowel disease","volume":"16","author":"Nicholson MR","year":"2022","unstructured":"Nicholson MR, Alexander E, Ballal S, et al.. Efficacy and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in children with inflammatory bowel disease. J Crohns Colitis. 2022, 16:768-77. 10.1093\/ecco-jcc\/jjab202","journal-title":"J Crohns Colitis"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016698","article-title":"Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial","volume":"7","author":"Pai N","year":"2017","unstructured":"Pai N, Popov J. Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial. BMJ Open. 2017, 7:e016698. 10.1136\/bmjopen-2017-016698","journal-title":"BMJ Open"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002995","article-title":"Pediatric patient and parent perceptions of fecal microbiota transplantation for the treatment of ulcerative colitis","volume":"73","author":"Popov J","year":"2021","unstructured":"Popov J, Hartung E, Hill L, Chauhan U, Pai N. Pediatric patient and parent perceptions of fecal microbiota transplantation for the treatment of ulcerative colitis. J Pediatr Gastroenterol Nutr. 2021, 73:684-8. 10.1097\/MPG.0000000000002995","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15607414","article-title":"Fecal microbiota transplantation: in perspective","volume":"9","author":"Gupta S","year":"2016","unstructured":"Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016, 9:229-39. 10.1177\/1756283X15607414","journal-title":"Therap Adv Gastroenterol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.826114","article-title":"Encapsulated fecal microbiota transplantation: development, efficacy, and clinical application","volume":"12","author":"Halaweish HF","year":"2022","unstructured":"Halaweish HF, Boatman S, Staley C. Encapsulated fecal microbiota transplantation: development, efficacy, and clinical application. Front Cell Infect Microbiol. 2022, 12:826114. 10.3389\/fcimb.2022.826114","journal-title":"Front Cell Infect Microbiol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.574533","article-title":"Fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update","volume":"11","author":"Tan P","year":"2020","unstructured":"Tan P, Li X, Shen J, Feng Q. Fecal microbiota transplantation for the treatment of inflammatory bowel disease: an update. Front Pharmacol. 2020, 11:574533. 10.3389\/fphar.2020.574533","journal-title":"Front Pharmacol"},{"key":"ref106","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold SL","year":"2021","unstructured":"Gold SL, Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature\r\n. Gastroenterol Hepatol (N Y). 2021, 17:406-14.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00472","article-title":"The emerging jamboree of transformative therapies for autoimmune diseases","volume":"11","author":"Carballido JM","year":"2020","unstructured":"Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kamm\u00fcller M. The emerging jamboree of transformative therapies for autoimmune diseases. Front Immunol. 2020, 11:472. 10.3389\/fimmu.2020.00472","journal-title":"Front Immunol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010016","article-title":"Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development","volume":"13","author":"Velikova T","year":"2024","unstructured":"Velikova T, Sekulovski M, Peshevska-Sekulovska M.  Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to anti-drug antibody development. Antibodies (Basel). 2024, 13:10.3390\/antib13010016","journal-title":"Antibodies (Basel)"},{"key":"ref109","article-title":"Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease","volume":"13","author":"Cheifetz A","year":"2017","unstructured":"Cheifetz A. Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017, 13:556-9.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206577","article-title":"A review of therapeutic drug monitoring in patients with inflammatory bowel disease receiving combination therapy","volume":"12","author":"Patel S","year":"2023","unstructured":"Patel S, Yarur AJ. A review of therapeutic drug monitoring in patients with inflammatory bowel disease receiving combination therapy. J Clin Med. 2023, 12:10.3390\/jcm12206577","journal-title":"J Clin Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000536","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?","volume":"35","author":"Papamichael K","year":"2019","unstructured":"Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?. Curr Opin Gastroenterol. 2019, 35:302-10. 10.1097\/MOG.0000000000000536","journal-title":"Curr Opin Gastroenterol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali T","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013, 5:79-99. 10.2147\/DHPS.S28801","journal-title":"Drug Healthc Patient Saf"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.955293","article-title":"Effects of psychosocial function in pediatric-onset inflammatory bowel disease during the coronavirus disease 2019 pandemic","volume":"11","author":"Zhang H","year":"2023","unstructured":"Zhang H, Yang Y, Zhao X, et al.. Effects of psychosocial function in pediatric-onset inflammatory bowel disease during the coronavirus disease 2019 pandemic. Front Pediatr. 2023, 11:955293. 10.3389\/fped.2023.955293","journal-title":"Front Pediatr"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1177\/1059840515615401","article-title":"Quality of life and school absenteeism in children with chronic illness","volume":"32","author":"Emerson ND","year":"2016","unstructured":"Emerson ND, Distelberg B, Morrell HE, Williams-Reade J, Tapanes D, Montgomery S. Quality of life and school absenteeism in children with chronic illness\r\n. J Sch Nurs. 2016, 32:258-66. 10.1177\/1059840515615401","journal-title":"J Sch Nurs"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz183","article-title":"Health care cost for children newly diagnosed with inflammatory bowel disease","volume":"26","author":"Fondell AW","year":"2020","unstructured":"Fondell AW, Mosha MH, Frank CR, Brangi JM, Hyams JS. Health care cost for children newly diagnosed with inflammatory bowel disease\r\n. Inflamm Bowel Dis. 2020, 26:635-40. 10.1093\/ibd\/izz183","journal-title":"Inflamm Bowel Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/326182-inflammatory-bowel-disease-in-children-current-diagnosis-and-treatment-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:23:31Z","timestamp":1738650211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/326182-inflammatory-bowel-disease-in-children-current-diagnosis-and-treatment-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":115,"URL":"https:\/\/doi.org\/10.7759\/cureus.78462","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}